Insider Selling: Bioventus (NYSE:BVS) Director Sells 17,701 Shares of Stock

Bioventus Inc. (NYSE:BVS) Director Michelle Mcmurry-Heath sold 17,701 shares of the company’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $7.42, for a total transaction of $131,341.42. Following the transaction, the director owned 56,997 shares of the company’s stock, valued at $422,917.74. This represents a 23.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Bioventus Price Performance

Shares of BVS stock traded up $0.04 on Monday, reaching $7.49. 280,642 shares of the company were exchanged, compared to its average volume of 379,906. Bioventus Inc. has a 1 year low of $5.81 and a 1 year high of $12.61. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The business has a 50-day moving average price of $6.94 and a 200 day moving average price of $6.87. The company has a market cap of $619.27 million, a price-to-earnings ratio of -12.28 and a beta of 0.80.

Hedge Funds Weigh In On Bioventus

Hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Bioventus by 7.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after acquiring an additional 1,538 shares during the last quarter. EntryPoint Capital LLC lifted its holdings in Bioventus by 7.8% in the 1st quarter. EntryPoint Capital LLC now owns 28,371 shares of the company’s stock valued at $260,000 after purchasing an additional 2,048 shares in the last quarter. Covestor Ltd boosted its stake in Bioventus by 28.0% during the 3rd quarter. Covestor Ltd now owns 9,951 shares of the company’s stock worth $67,000 after purchasing an additional 2,176 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in Bioventus by 12.0% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 24,482 shares of the company’s stock worth $162,000 after purchasing an additional 2,615 shares during the last quarter. Finally, EP Wealth Advisors LLC grew its holdings in shares of Bioventus by 24.1% during the first quarter. EP Wealth Advisors LLC now owns 17,490 shares of the company’s stock worth $160,000 after buying an additional 3,394 shares in the last quarter. Institutional investors and hedge funds own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.